US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE PHARMA GROUP

38.58

-2.7300-6.61%

Post-market: 38.29-0.2900-0.75%16:10 EDT

Volume:22.91K

Turnover:886.83K

Market Cap:3.59B

PE:-52.45

High:39.58

Open:38.65

Low:38.00

Close:41.31

52wk High:48.45

52wk Low:16.50

Shares:92.96M

Float Shares:71.58M

Volume Ratio:3.45

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7356

EPS(LYR):-0.7356

ROE:-159.65%

ROA:-22.77%

PB:38.44

PE(LYR):-52.45

Loading ...

Overview Company News Filings

Ascentage Pharma Announces Proposed Top-Up Placement

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

Ascentage Pharma names Dr. Veet Misra as CFO

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

High Growth Tech Stocks in Asia to Watch This April 2025

Simply Wall St.

Asian Growth Companies With High Insider Ownership

Simply Wall St.

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines

Ascentage Pharma Says 2 Investigational Drugs Added to 2025 CSCO Guidelines

MT Newswires Live

Analysts’ Top Healthcare Picks: Ascentage Pharma Group International Unsponsored ADR (AAPG), BioNTech SE (BNTX)

Stock Track | Ascentage Pharma Soars 8.76% on Strong 2024 Results and Pipeline Progress

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

MT Newswires Live

Stock Track | Ascentage Pharma Soars 8.60% Pre-Market on Strong 2024 Financial Results and Pipeline Progress

Ascentage Pharma Group's 2024 Loss Narrows, Revenue Rises

MT Newswires Live

Earnings Flash (AAPG) Ascentage Pharma Posts 2024 Revenue 980.7M Chinese Renminbi

MT Newswires Live

Earnings Flash (AAPG) Ascentage Pharma Group Posts Full Year 2024 Loss of 1.34 Chinese Renminbi a Share

MT Newswires Live

Press Release: Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAPG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":38.58,"timestamp":1757016000000,"preClose":41.31,"halted":0,"volume":22912,"hourTrading":{"tag":"盘后","latestPrice":38.29,"preClose":38.58,"latestTime":"16:10 EDT","volume":32,"amount":1225.28,"timestamp":1757016603677},"delay":0,"floatShares":71582800,"shares":92963368,"eps":-0.735552,"marketStatus":"Post-Mkt","change":-2.73,"latestTime":"09-04 18:38:07 EDT","open":38.6486,"high":39.5754,"low":38,"amount":886829.8183,"amplitude":0.038136,"askPrice":48.8,"askSize":200,"bidPrice":37.5,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1757030400000},"marketStatusCode":4,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.31,"preHourTrading":{"tag":"盘前","latestPrice":39,"preClose":41.5,"latestTime":"09:19 EDT","volume":3079,"amount":121188.63946,"timestamp":1756991960683},"postHourTrading":{"tag":"盘后","latestPrice":38.29,"preClose":38.58,"latestTime":"16:10 EDT","volume":32,"amount":1225.28,"timestamp":1757016603677},"volumeRatio":3.450394},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":3.450394,"shares":92963368,"dividePrice":0,"high":39.5754,"amplitude":0.038136,"preClose":41.31,"low":38,"week52Low":16.5,"pbRate":"38.44","psRate":"65.54","week52High":48.45,"institutionHeld":0,"latestPrice":38.58,"committee":-0.904762,"eps":-0.735552,"divideRate":0,"volume":22912,"delay":0,"ttmEps":-0.735552,"open":38.6486,"prevYearClose":17.25,"prevWeekClose":42.47,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":41.4,"twentyDayClose":42.68,"sixtyDayClose":29.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-03","current":-23.296307,"percent":1,"low":-76.454813,"twenty":-59.787237,"median":-36.496563,"eighty":-32.375664,"high":-23.296307,"avg":-42.855108,"sd":14.066163,"marketCap":3780906582.56},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-03","current":-23.296307,"twenty":-59.787237,"median":-36.496563,"eighty":-32.375664,"marketCap":3780906582.56}],"updateTime":1756991622133},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551901751","title":"Ascentage Pharma Announces Proposed Top-Up Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901751","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551901751?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:23","pubTimestamp":1752484980,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  14, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3114569/0/en/Ascentage-Pharma-Announces-Proposed-Top-Up-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2550625666","title":"Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2550625666","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550625666?lang=en_us&edition=fundamental","pubTime":"2025-07-10 21:30","pubTimestamp":1752154200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  10, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in can","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/10/3113419/0/en/Ascentage-Pharma-Announces-Its-Novel-Bcl-2-Inhibitor-Lisaftoclax-Approved-by-China-NMPA-Ushering-in-a-New-Era-for-the-Treatment-of-CLL-SLL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","TLS","SG9999015945.SGD","LU1066051498.USD","LU0950375773.USD","ORR","SG9999002232.USD","LU2286300806.USD","IE00BKVL7J92.USD","LU1267930813.SGD","LU0203347892.USD","LU2237443978.SGD","SG9999015952.SGD","LU1883839398.USD","LU2506951875.HKD","LU1221951129.SGD","AAPG","LU2247934214.USD","LU0203345920.USD","BK4525","LU0234572021.USD","CSCO","BK4533","IE00BVYPNV92.GBP","LU1221951046.USD","LU2237443549.SGD","LU1046421795.USD","BK4515","LU1506573853.SGD","LU1059921491.USD","BK4097","BK4581","LU1244550577.SGD","LU0889566641.SGD","LU1894683348.USD","PPI","BK4588","LU2237443465.HKD","SG9999015978.USD","BK4570","SG9999015986.USD","IE00B3T34201.USD","BK4139","LU1894683264.USD","LU1880398471.USD","SG9999001440.SGD","LU2506952170.USD","LU0348723411.USD","LU0823417653.USD","IE00BVYPNW00.USD"],"gpt_icon":0},{"id":"2549666975","title":"Ascentage Pharma names Dr. Veet Misra as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2549666975","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549666975?lang=en_us&edition=fundamental","pubTime":"2025-07-08 07:35","pubTimestamp":1751931309,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) announced the appointments of Veet Misra, Ph.D., as the company’s Chief Financial Officer, and Mr. Eric Huang, as Senior Vi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-names-dr-veet-misra-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-names-dr-veet-misra-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2549525566","title":"Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2549525566","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549525566?lang=en_us&edition=fundamental","pubTime":"2025-07-08 07:30","pubTimestamp":1751931000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  07, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3111397/0/en/Ascentage-Pharma-Appoints-Dr-Veet-Misra-as-Chief-Financial-Officer-and-Eric-Huang-as-Senior-Vice-President-of-Global-Corporate-Development-and-Finance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2544590685","title":"Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2544590685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544590685?lang=en_us&edition=fundamental","pubTime":"2025-06-18 22:49","pubTimestamp":1750258174,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were rising Wednesday morning, up 0.4% to 2,283.81 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by pharmaceutical company Ascentage  and financial service provider CNFinance , which advanced 11% and 6.9%, respectively.They were followed by biotech firm Adlai Nortye , which climbed 3.3%.The decliners from North Asia were led by cryptocurrency mining company BIT Mining  and computer hardware maker Canaan , which fell 9% and 2.2%, respectively.They were followed by technology company Baidu , down 1%.The decliners from South Asia were led by technology firm Wipro , which was down 0.8%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4552","BK4600","BK4588","BK4523","LU1023057109.AUD","LU0359201612.USD","BK4548","AAPG","BK7502","CNF","ANL.AU","BIDU","LU0173614495.USD","BK7104","LU0640798160.USD","LU1115378108.SGD","BK4602","BK4023","WIT","BK7096","BK4117","BK4585","BK4504","BK4574","AFG","BK4587","LU0359202008.SGD","BK4139","BK4195","BK4526","BK7508","BK4612","LU0287142896.SGD","BK4077","BK4514","BK4614","CAN","BK4134","BK4535","IE00B0JY6N72.USD","BK4229","BTCM","BK4543","BK4531","BK4170","BK4579","BK4107","BK4595","ANL","CAN.AU"],"gpt_icon":1},{"id":"2530892358","title":"High Growth Tech Stocks in Asia to Watch This April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530892358","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530892358?lang=en_us&edition=fundamental","pubTime":"2025-04-25 12:38","pubTimestamp":1745555888,"startTime":"0","endTime":"0","summary":"As of mid-April 2025, smaller-cap indexes like the S&P MidCap 400 and Russell 2000 have shown resilience by posting gains, even as large-cap tech stocks in the U.S. faced headwinds due to new trade restrictions with China. In this environment of mixed market signals and ongoing trade tensions, investors might consider focusing on high-growth tech stocks in Asia that demonstrate strong fundamentals and adaptability to global economic shifts.SEHK:6855 Earnings and Revenue Growth as at Apr 2025. Overview: Guangdong Shenglu Telecommunication Tech is a company engaged in the design, development, and manufacturing of telecommunication equipment with a market cap of CN6.11 billio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-asia-043808151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2530992330","title":"Asian Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2530992330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530992330?lang=en_us&edition=fundamental","pubTime":"2025-04-25 12:35","pubTimestamp":1745555735,"startTime":"0","endTime":"0","summary":"Amidst a backdrop of global trade tensions and economic uncertainties, Asian markets have shown resilience, with China's stock indices advancing on the expectation of increased stimulus measures. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.Top 10 Growth Companies With High Insider Ownership In Asia. Ascentage Pharma Group International, a growth-focused biotech company in Asia, showcases high insider ownership and robust R&D capabilities. Recently, its novel drugs lisaftoclax and olverembatinib received significant recognition in the 2025 CSCO Guidelines, enhancing their clinical credibility. Despite past shareholder dilution and share price volatility, Ascentage's revenue is forecast to grow at 22.2% annually, outpacing the Hong Kong market. The company reported CNY 980.65 million in sales for 2024 with a reduced net loss of CNY 405.43 million compared to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asian-growth-companies-high-insider-043535217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2529569508","title":"Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin","url":"https://stock-news.laohu8.com/highlight/detail?id=2529569508","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529569508?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, April 23, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical studies of the Bcl-2 selective inhibitor lisaftoclax  and the MDM2-p53 inhibitor alrizomadlin , two key drug candidates in the company’s apoptosis-targeted pipeline, have been selected for presentations at the 2025 American Society of Clinical Oncology  Annual Meeting. These presentations will include an oral report featuring updated results from a Phase Ib/II study of a lisaftoclax combination regimen in patients with myeloid malignancies.The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community, bringing togethe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-present-data-two-230000349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AAPG","BK4202","NCI"],"gpt_icon":0},{"id":"2529511553","title":"Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2529511553","media":"Exec Edge","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529511553?lang=en_us&edition=fundamental","pubTime":"2025-04-22 06:10","pubTimestamp":1745273405,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group Internat  said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology  Guidelines.The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.“The recommendations for both olverembatinib and lisaftoclax  in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-drugs-included-chinese-221005131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B42XCP33.USD","IE00BVYPNV92.GBP","LU1244550577.SGD","SG9999001424.SGD","IE00B3PB1722.GBP","LU2237443549.SGD","LU0234570918.USD","LU1066051498.USD","LU0234572021.USD","LU2506952097.USD","BK4020","IE00BSNM7G36.USD","LU1059921491.USD","LU2286300806.USD","BK4588","IE00BGHQF631.EUR","LU0792757196.USD","BK4139","SG9999002232.USD","IE00BFMHRM44.USD","IE00BFXG1179.USD","BK4533","LU0203345920.USD","LU1883839398.USD","BK4527","LU2506951958.HKD","LU1046421795.USD","LU1430594728.SGD","IE00BKVL7J92.USD","BK4525","IE00B3T34201.USD","LU2506951875.HKD","LU1244550494.USD","IE00BDGV0183.EUR","BK4550","LU0950375773.USD","SG9999015986.USD","LU2237443622.USD","LU1599440770.SGD","LU0203347892.USD","LU1066051225.USD","LU1506573853.SGD","LU1585245621.USD","SG9999015978.USD","AAPG","BK4515","LU2237443978.SGD","CSCO","LU1880398554.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2529809358","title":"Ascentage Pharma Says 2 Investigational Drugs Added to 2025 CSCO Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2529809358","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529809358?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:53","pubTimestamp":1745240026,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) said Monday that two of its drug candidates, lisaftoclax and olverembatinib, were included in the 2025 Chinese Society of Clinical Oncology Guidelines.The company said lisaftoc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B42XCP33.USD","LU1066051225.USD","IE00B3PB1722.GBP","LU0234570918.USD","SG9999015986.USD","LU1235294995.USD","LU0203347892.USD","LU0792757196.USD","BK4588","LU1244550494.USD","BK4612","LU2506952097.USD","LU0942090050.USD","LU0868494617.USD","LU1244550221.USD","LU1571399168.USD","CSCO","LU1894683264.USD","LU0868494708.USD","BK4581","LU2247934214.USD","LU2506951958.HKD","IE00BZ1G4Q59.USD","LU0234572021.USD","LU1823568750.SGD","SG9999015945.SGD","IE00BFXG1179.USD","LU0203345920.USD","LU1430594728.SGD","LU2506952170.USD","SG9999015952.SGD","LU2237443895.HKD","AAPG","LU0731783394.SGD","LU0823417653.USD","IE00B3T34201.USD","LU1883839398.USD","BK4525","LU1267930813.SGD","LU2237443549.SGD","SG9999001424.SGD","SG9999001440.SGD","LU0889566641.SGD","IE00BFMHRM44.USD","BK4534","LU0823417737.USD","BK4515","LU2286300806.USD","LU2237443465.HKD","LU2237443382.USD"],"gpt_icon":0},{"id":"2523618284","title":"Analysts’ Top Healthcare Picks: Ascentage Pharma Group International Unsponsored ADR (AAPG), BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523618284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523618284?lang=en_us&edition=fundamental","pubTime":"2025-03-29 23:50","pubTimestamp":1743263421,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ADR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-ascentage-pharma-group-international-unsponsored-adr-aapg-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-ascentage-pharma-group-international-unsponsored-adr-aapg-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","HCSG","BK4548","BK4551","BK4588","BK4139","BK4568","BK4585","BK4137","AAPG","BNTX"],"gpt_icon":0},{"id":"1157491643","title":"Stock Track | Ascentage Pharma Soars 8.76% on Strong 2024 Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1157491643","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157491643?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:53","pubTimestamp":1743083581,"startTime":"0","endTime":"0","summary":"Shares of Ascentage Pharma Group International  surged 8.76% in Thursday's pre-market trading following the release of the company's impressive unaudited financial results for the full year 2024. The biopharmaceutical firm, focused on developing innovative therapies for hematological malignancies, reported significant revenue growth and pipeline advancements, signaling strong progress in its oncology-focused business.Investors were particularly encouraged by Ascentage Pharma's pipeline progress.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AAPG"],"gpt_icon":0},{"id":"2522305430","title":"Sector Update: Health Care Stocks Flat to Higher Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305430","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305430?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:12","pubTimestamp":1743081128,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Thursday, with The Health Care Select Sector SPDR Fund (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) inactive.Soleno Therapeutics (SLNO) shares","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLCO","BK4139","XLV","BK4581","BK4588","SLNO","BK4198","AAPG","IBB","BK4585"],"gpt_icon":0},{"id":"1146804408","title":"Stock Track | Ascentage Pharma Soars 8.60% Pre-Market on Strong 2024 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1146804408","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146804408?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:14","pubTimestamp":1743077693,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International  saw its stock surge 8.60% in pre-market trading on Thursday following the release of its unaudited financial results for the full year 2024. The company reported significant revenue growth and pipeline advancements, signaling strong progress in its oncology-focused business.- Revenue increased 342% year-over-year to US$134.3 million . - Loss narrowed to US$55.6 million, down from US$127.4 million in 2023. - Sales of olverembatinib in China grew 52% to US$33.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Ascentage Pharma Soars 8.60% Pre-Market on Strong 2024 Financial Results and Pipeline Progress","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AAPG"],"gpt_icon":0},{"id":"2522718083","title":"Ascentage Pharma Group's 2024 Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2522718083","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522718083?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:33","pubTimestamp":1743075201,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group  reported a 2024 loss Thursday of 1.34 renminbi  per diluted share, narrower than a loss of 3.28 renminbi a year earlier.Revenue for the year ended Dec. 31 was 980.7 million renminbi compared with 222 million renminbi a year earlier.Analyst estimates were not available for comparison.As of Dec. 31, 2024, cash and bank balances were 1.26 billion renminbi, compared to 1.09 billion renminbi a year earlier.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG"],"gpt_icon":0},{"id":"2522375415","title":"Earnings Flash (AAPG) Ascentage Pharma Posts 2024 Revenue 980.7M Chinese Renminbi","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375415","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375415?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:06","pubTimestamp":1743073592,"startTime":"0","endTime":"0","summary":"Earnings Flash (AAPG) Ascentage Pharma Posts 2024 Revenue 980.7M Chinese Renminbi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG"],"gpt_icon":0},{"id":"2522937541","title":"Earnings Flash (AAPG) Ascentage Pharma Group Posts Full Year 2024 Loss of 1.34 Chinese Renminbi a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522937541","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522937541?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:05","pubTimestamp":1743073552,"startTime":"0","endTime":"0","summary":"Earnings Flash (AAPG) Ascentage Pharma Group Posts Full Year 2024 Loss of 1.34 Chinese Renminbi a Share","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG"],"gpt_icon":0},{"id":"2522755023","title":"Press Release: Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522755023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522755023?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"-- Revenue in 2024 increased 342% year-over-year to US$134.3 million. , attributable in part to Takeda's option payment and. -- Sales of olverembatinib in China in 2024 increased 52% year-over-year to. -- Completion of U.S. initial public offering on Nasdaq in January 2025,27, 2025 and Chinese  investor event with simultaneous. Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, said, \"As we reflect on our achievements in 2024, I am delighted to report that Ascentage Pharma has made remarkable strides in advancing our mission to deliver innovative therapies to patients worldwide. The commercialization of olverembatinib in China has gained significant traction in 2024 and is poised for growth in 2025 as all approved indications of olverembatinib are now covered under China's National Reimbursement Drug List , markedly enhancing affordability and accessibility for patients across China.\". \"Our clinical development programs also achieved significant progress over the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HR","BK4008","BK4203","BK1161","5BI.SI","BK1574","06855","BK6008","BK4500","BK6514","BK4585","AAPG","BK4139","CDE","BK4017","ALK","DTP","BK4225","BK4588"],"gpt_icon":0},{"id":"2522830355","title":"Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522830355","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522830355?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:00","pubTimestamp":1742943600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md.and SUZHOU, China, March 25, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Meeting , taking place April 25-30, 2025, in Chicago, Illinois, USA.The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib , Bcl-2 inhibitor lisaftoclax , FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist AS03157.The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-present-five-preclinical-230000161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","AFG","BK4213","AAPG","BK4139","BK4107","AR"],"gpt_icon":0},{"id":"2517119981","title":"Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517119981","media":"Exec Edge","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517119981?lang=en_us&edition=fundamental","pubTime":"2025-03-07 06:18","pubTimestamp":1741299507,"startTime":"0","endTime":"0","summary":"Ascentage Pharma  said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia  indications and included in China’s National Reimbursement Drug List.Ph+ ALL, which accounts for 20%-30% of adult ALL cases, has poor treatment tolerance and prognosis, with existing first- and second-generation tyrosine kinase inhibitors  facing limitations such as high relapse rates, they said.“We are much encouraged to have olverembatinib’s clinical value once again recognized by the regulatory authority in China,” Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said. “This BTD underscores the therapeutic potential and utility of olverembatinib in Ph+ ALL, a hematologic malignancy with dismal prognosis. Moving forward, we will strive to accelerate this clinical development program for olverembatinib and bring it to more patients as quickly as possible.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-secures-third-breakthrough-therapy-221827310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAPG","ALL","BK4588","LU0985320562.USD","LU1571399168.USD","BK4107","LU1699723380.USD","BK4533","BK4139","LU2355687059.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}]}}